Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. The incidence of HCC is strikingly higher in males than in females. The remarkable gender disparity suggests an important role for sex hormones in HCC pathogenesis. Recently, estrogen has emerged as a protective factor in the development and progression of HCC, but whether it prevents and attenuates HCC, and the mechanism of protection, have not been elucidated. The present study shows that expression of estrogen receptor (ER) β was significantly downregulated in HCC tissue compared with normal liver tissue; moreover, its expression level showed a significant negative correlation with disease progression and a positive correlation with the expression level of NLRP3 inflammasome components. In a previous study, we showed that loss of NLRP3 inflammasome in HCC tissue contributed to tumor progression, whereas the mechanism of its deregulation was not elucidated. In this study, we investigated the potential link between NLRP3 inflammasome and estrogen. Our data reveal that treatment with 17β-estradiol (E2) significantly inhibited the malignant behavior of HCC cells through E2/ERβ/ MAPK pathway-mediated upregulation of the NLRP3 inflammasome. This study shows a novel link between ERβ and the NLRP3 inflammasome in HCC progression, which provides a potentially valuable therapeutic strategy for treatment of HCC patients.
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. The incidence of HCC is strikingly higher in males than in females. The remarkable gender disparity suggests an important role for sex hormones in HCC pathogenesis. Recently, estrogen has emerged as a protective factor in the development and progression of HCC, but whether it prevents and attenuates HCC, and the mechanism of protection, have not been elucidated. The present study shows that expression of estrogen receptor (ER) β was significantly downregulated in HCC tissue compared with normal liver tissue; moreover, its expression level showed a significant negative correlation with disease progression and a positive correlation with the expression level of NLRP3 inflammasome components. In a previous study, we showed that loss of NLRP3 inflammasome in HCC tissue contributed to tumor progression, whereas the mechanism of its deregulation was not elucidated. In this study, we investigated the potential link between NLRP3 inflammasome and estrogen. Our data reveal that treatment with 17β-estradiol (E2) significantly inhibited the malignant behavior of HCC cells through E2/ERβ/ MAPK pathway-mediated upregulation of the NLRP3 inflammasome. This study shows a novel link between ERβ and the NLRP3 inflammasome in HCC progression, which provides a potentially valuable therapeutic strategy for treatment of HCC patients. Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and the third-leading cause of cancer-related mortality in the world. 1 It is well recognized that HCC is a male-dominant disease. Rates of liver cancer in males are typically 2 to 4 times higher than in females, and males usually have a poorer prognosis than females. 2 The remarkable gender disparity observed in the incidence of HCC suggests that the sex steroid hormone estrogen may elicit a protective effect against this disease. [3] [4] [5] The biological functions of 17β-estradiol (E2), a major form of estrogen, are mainly mediated by its two specific estrogen receptors, ERα and ERβ. The role of ERα in carcinogenesis has been widely investigated and elucidated, whereas ERβ was first identified in 1996 (ref. 6 ) and the function of ERβ in HCC is not known. Moreover, the precise role of estrogen and the expression status of ERβ receptors in HCC still remain poorly understood. Therefore, in this study, we investigated the effect of E2 and its downstream signaling in HCC development.
The NLRP3 inflammasome is an intracellular multiprotein complex involved in the innate immune response to pathogens and other hazards. Our previous work demonstrated that expression of NLRP3 inflammasome components was significantly downregulated in HCC tissue compared with that in the adjacent non-cancerous tissue, and that the deregulation of the NLRP3 inflammasome was involved in HCC progression. 7 On the basis of the involvement of E2 in hepatocarcinogenesis 5, 8, 9 and its newly defined role in regulation of some NLRP3 inflammasome components, 10 we speculated that E2 might be responsible for the deregulation of NLRP3 inflammasome in HCC progression and thus contribute, to a certain degree, to the gender disparity in HCC.
In this study, we investigated the potential link between estrogen and the NLRP3 inflammasome. Our data show that expression of ERβ, one of the E2 receptors, was significantly downregulated in HCC tissue, and that its expression level positively correlated with the presence of NLRP3 inflammasomes in HCC patients. Moreover, E2 treatment significantly increased the expression and activation of NLRP3 inflammasomes in HCC cells, which further led to a reversal of malignant behavior of HCC cells. These data reveal a surprising regulatory role of E2 in the carcinogenesis and progression of HCC, which indicate that gender disparity in HCC patients is caused, at least to a certain degree, by E2 through ERβ.
MATERIALS AND METHODS
Patients, Specimens, and Tissue Microarray Construction A total of 127 primary HCC samples and the paired adjacent non-cancer liver tissue were used for the tissue microarray (TMA) construction (Shanghai Biochip, Shanghai, China). There were 110 men (86.6%) and 17 women (13.4%) with a mean age of 54.0 years. Detailed clinicopathologic characteristics of these 127 HCC cases were shown in Table 1 . To validate the results of immunohistochemistry (IHC) analysis of TMAs, real-time PCR analysis was conducted from the paired liver cancer tissue and non-cancerous liver tissue from another cohort of 24 HCC patients. Furthermore, western blot analysis was carried out from the third cohort of 64 HCC patients. All of the enrolled patients were those underwent curative resection in the Department of Hepatobiliary Surgery of the Provincial Hospital Affiliated to Shandong University from February 2012 to July 2014. No patients received chemotherapy or radiotherapy before surgical resection. Cell differentiation based on tumor grading was determined using the Edmondson grading system, and clinical stages were classified according to the International Union against Cancer TNM classification system. Written ethical approvals were obtained from all of these patients before the initiation of this study. All of the protocols dealing with the patients were conformed to the ethical guidelines of the Helsinki Declaration and approved by Shandong University Research Ethics Committee.
Immunohistochemical Staining and Scoring IHC was performed as previously described. 7 The primary antibodies included rabbit monoclonal anti-human ASC (#ADI-905-173, Enzo Life Sciences, San Diego, CA), IL-1β (#ab2105, Abcam, Cambridge, MA), caspase 1 (#AP6703c Abgent, Shanghai, China), ERβ (#bs-0116R, Biosynthesis Biotechnology, Beijing, China), and mouse monoclonal antihuman NLRP3 (#ab17267, Abcam). TMA slides were incubated with primary antibodies at 4°C overnight, and then washed with PBS for three times. The slides were then incubated with biotinylated secondary antibody for 1 h. Reaction products were visualized by incubating slides with 3,3′-diaminobenzidine, followed by counterstained with hematoxylin, dehydrated in alcohol and xylene, mounted in neutral gum, and analyzed using a bright field microscope.
The analysis of TMA slides was performed by two pathologists who were blinded to the clinical data, and the IHC staining degree was represented by the staining intensity. The intensity score was then classified into 4 scales, with 0 = negative, 1 = weak, 2 = moderate, and 3 = strong. Grade 0 and 1 were classified as low expression and grade 2 and 3 were considered as high expression. In parallel, immunohistochemical After the reaction, 10 μl of the PCR products were used for running in agarose gels, stained with ethidium bromide, and visualized using UV transillumination.
qRT-PCR was carried out using a Light Cycler (Bio-Rad, CFX96, USA) according to the manufacturer's instructions. Each sample was examined in triplicate and β-actin was used as the internal control. The primers we used for real-time PCR is listed in the online Supplementary Data. GraphPad Prism v5 (GraphPad Software, San Diego, CA, USA) was used to create the scatter plots. Data shown are representative figure from at least three independent experiments.
Western Blot Analysis
Total protein extractions were obtained from HCC cells or fresh liver tissue, and lysed in RIPA buffer before separated by SDS-polyacrylamide gel electrophoresis. The cell culture supernatant was collected and concentrated using the Amicon Ultra 10 K Centrifugal Filter Devices (Millipore, Billerica, MA, USA) before western blot assay. The primary antibodies included antibody against ERβ (#ab3576) from Abcam company; antibodies against NLRP3 (#ALX-804-818-C100) and ASC (#ADI-905-173) from Enzo Life Sciences; antibodies against caspase 1 (#S3866) and IL-1β (#S2022) from Cell Signaling Technology (Danvers, MA, USA). β-Actin protein was detected as an internal control using the mouse anti-β-actin monoclonal antibody (#ab6276, Abcam).
Inflammasome Reconstitution NLRP3 inflammasome reconstitution was performed by transfecting the cells with eukaryotic expression plasmids, including 15 ng of pcDNA3-myc-NLRP3, 5 ng of pcDNA3-myc-ASC, 5 ng of pcDNA3-myc-procaspase1, and 150 ng of pRC/cMV-proIL-1β, using Lipofectamin 2000 from Invitrogen (Grand Island, NY, USA). The inflammasome components expression plasmids were kind gifts from Dr John C. Reed and the construction of these plasmids were described in the references. 13, 14 HCC cells were seeded in 24-well plates and incubated for 24 h before transient transfection with plasmids encoding NLRP3 inflammasome. Cells transfected with empty pcDNA3 plasmid were used as a mock control. Successful inflammasome reconstitution was confirmed by mRNA and protein assay of NLRP3 inflammasome components by RT-PCR and western blot, respectively. Caspase 1 activation was analyzed using a Caspase-1 Colorimetric Assay Kit (BioVision, CA, USA) according to its protocol. Secretion of IL-1β in the supernatant from inflammasome reconstituted cells was detected using ELISA kits (Dakewe Biotech Company, Shenzhen, China) according to the manufacturer's instruction.
Cell Viability, Cell Death, and Colony Formation Assay Cell viabilities were analyzed using a CCK-8 kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacture's instruction. Cell death was detected by trypan blue staining and LDH release assay kit (Beyotime Biotechology, Beijing, China) according to the manuscripture's instruction. For the colony formation assay, HCC cells were seeded in sixwell plate at a density of 1 × 10 3 cells per well. After 7 days of incubation, survival colonies (450 cells per colony) were stained with 0.5% of crystal violet and counted under the microscope. The experiments were carried out in triplicate and repeated for at least three times.
Cell Migration Assay
Cell migration capability was studied by transwell migratory assay and wound healing assay. The transwell migratory assay was carried out using the transwell migratory apparatus (Costar, 6.5-mm diameter, 8-μm pore size) as described before. 5 For the wound healing assay, HCC cells were plated in the 24-well plate and incubated for 24 h. Cell monolayers were then carefully wounded using a sterile 200-μl pipette tip to generate a cut of~1 mm in width. After washing twice with PBS, cells were incubated in RPMI 1640 growth medium containing 3% FBS for 24 h. Distance of cell migration was determined by measuring width of the wound and calculated using the width difference from treated HCC cells divided by that from mock control cells.
Statistical Analysis
Data were analyzed using SPSS 16.0 (SPSS, IL, USA) and a P-value of o0.05 was considered statistically significant. χ variables and continuous variables, respectively. Spearman's rank correlation test was used to evaluate correlations between variables.
RESULTS

ERβ Expression was Significantly Downregulated in HCC Tissue
On the basis of our preliminary results showing deregulation of NLRP3 inflammasomes in HCC progression and the potential role of E2 in HCC development, we examined whether E2 was involved in HCC progression by its regulation of NLRP3 inflammasomes. To define the role of E2 in NLRP3 inflammasome deregulation in HCC, we determined the expression of ERβ in HCC tissue and corresponding noncancerous liver tissue using IHC. Our IHC data show that ERβ expression was significantly downregulated in HCC tissue compared with that in adjacent non-cancerous liver tissue (Figure 1a) . A χ 2 -test analysis showed significantly decreased ERβ immunoreactivity in HCC tissue compared with that of the corresponding non-cancerous liver tissue (41.7 vs 93.7%, Po0.001, Table 2 ). The decreased expression tendency of ERβ in HCC tissue was confirmed by real-time PCR (Po0.001, Figure 1b) . Validation of the expression tendency of ERβ was further performed by western blot analysis in paired HCC tissue and non-cancerous liver tissue from another cohort of 64 HCC patients. Our western blot data also confirmed the decreased expression of ERβ in HCC tissue (Po0.001, Figure 1c and d) .
ERβ Deficiency Correlated with Advanced HCC Pathological Grades and TNM Stages
We have shown that expression of ERβ was significantly decreased in HCC tissue; therefore, we wished to determine whether this downregulation correlated with disease progression. IHC staining data showed that HCC patients with more advanced pathological grades and clinical stages tended to exhibit lower ERβ immunoreactivity (Figure 1e and f) . This decreased expression of ERβ in advanced pathological grades of HCC tissue was further confirmed using Image Pro Plus v6.2 analysis(Po0.01, Figure 1g ). Spearman correlation analysis was performed between ERβ expression and clinicopathological characteristics based on the IHC scores, which showed that ERβ protein levels significantly negatively correlated with the clinical stages and pathological grades of the HCC patients (Po0.001, Table 3 ). These results indicate a potential involvement of E2 in the HCC progression via its ERβ receptor.
ERβ Expression Positively Correlated with NLRP3 Inflammasome Components
Our previous study showed that expression of NLRP3 inflammasome components was significantly downregulated in HCC tissue and its expression level showed significant negative correlation with disease progression. 7 On the basis of the same expression tendency of ERβ, we believed that ERβ expression may also be correlated with the expression levels of NLRP3 inflammasome components. Statistical analysis of the IHC scores indeed defined positive correlations between the expression level of ERβ and that of NLRP3 inflammasome components, including NLRP3, ASC, caspase 1, and IL-1β (Po0.001, Table 4 ). In addition, real-time PCR data also revealed that expression level of ERβ showed significant positive correlation with expression of NLRP3 inflammasome components (Po0.05, Figure 2 ).
The NLRP3 Inflammasome was Upregulated by E2 in the ERβ/MAPK/ERK Pathway In order to further define the regulatory role of E2 for NLRP3 inflammasome components, we treated the HCC cell with E2 (Figure 3a and b) , which was further confirmed at the protein level using western bloting (Figure 3c ). Western blot data also showed that upregulation of NLRP3 inflammasome components was coordinated with MAPK/ERK pathway activation after E2 treatment (Figure 3c ), which indicated that NLRP3 inflammasome was upregulated by E2 through ERβ/MAPK/ ERK pathway. To further verify this mechanism, we pretreated the HCC cells with ERβ-specific inhibitor THTPP or MAPK pathway inhibitor PD98059 before E2 treatment, and detected the expression of NLRP3 inflammasome. Our data show that incubation of HCC cells with either THTPP or PD98059 could efficiently abrogate the increased expression of NLRP3 inflammasome components, which was both confirmed at protein level using western blot (Figure 3d and e) and at mRNA level using real-time PCR (Figure 3f ). These results demonstrated that E2 stimulation induced significant upregulation of NLRP3 inflammasome components through ERβ/MAPK/ERK pathway.
Reconstitution of NLRP3 Inflammasome Reversed Malignant Behaviors of HCC Cells
We have demonstrated that NLRP3 inflammasome expression was downregulated in HCC patients, and their decreased expression correlated with poorer cell differentiation and advanced clinical stages; 7 then, we asked whether deregulation of NLRP3 inflammasome in HCC contributed to cancer progression. To answer this question and further define the role of NLRP3 inflammasome molecular platform in liver cancer, we reconstituted NLRP3 inflammasome in HCC cells and investigated the change of malignant behaviors of these cells. HCC cells were transiently co-transfected with plasmids encoding NLRP3, ASC, pro-Caspase1, and pro-IL-1β. Significantly increased expression of each component of NLRP3 inflammasome in the reconstituted HCC cells was confirmed Caspase 1 undergoes autoproteolysis once the inflammasome is formed, further cleaves its downstream molecules, and releases the mature form of IL-1β, 15 so we detected both of the pro-form and cleaved form of caspase 1 and IL-1β in the inflammasome reconstituted cells. As shown in Figure 4b , the cleaved form of caspase 1 and IL-1β were significantly increased (in both the cell lysates and supernatants) in the NLRP3 inflammasome-reconstituted cells compared with mock control. These data indicated successful reconstitution of NLRP3 inflammasome in HCC cells. Then, we detected a series of malignant behaviors of HCC cells in these inflammasome reconstituted cells. Cell viability was investigated by CCK-8 assay and our data indicate that inflammasome reconstituted cells exhibited decreased cell viability, which revealed that reconstitution of NLRP3 inflammasome significantly inhibited proliferation of these HCC cells (Figure 4c and d) . Trypan blue staining and LDH release assay showed that NLRP3 inflammasome reconstitution significantly induced cell death of these HCC cells (Figure 4e, f and g ). It is well recognized that NLRP3 inflammasome activation induced caspase 1-dependent cell death, named pyroptosis. 16, 17 Caspase 1 activation assay and IL-1β ELISA assay showed that significant caspase 1 activation (Figure 4h and i) and IL-1β secretion (Figure 4j and k) were detected in the NLRP3 inflammasome reconstituted cells. These data indicate that NLRP3 inflammasome reconstitution induced caspase 1-dependent pyroptosis. To further verify the migratory capability of NLRP3 inflammasome in the malignant behaviors of these HCC cells, we performed transwell migratory assay and wound healing assay in these NLRP3 inflammasome reconstituted HCC cells. Transwell migratory assay showed that NLRP3 inflammasome reconstituteion significantly inhibited migratory capability of HCC cells (Po0.01, Figure 4l) , which was further confirmed by wound healing assay (Po0.05, Figure 4m and n) . Altogether, Figure 5f and g); whereas blockage of E2/ERβ/MAPK/ ERK pathway by incubation with its specific inhibitors PHTPP and PD98059 effectively reversed the inhibitory effect of E2 on HCC cells (Po0.05, Figure 5a-g ). These data further confirmed that E2-mediated reversion of malignant behaviors of HCC cells through ERβ/MAPK/ERK pathway.
E2 Reversed Malignant Behaviors of HCC Cells by its Upregulation of NLRP3 Inflammasome
Our data indicate that E2 increased expression of NLRP3 inflammasome components, and inflammasome reconstitution reversed the malignant behaviors of HCC cells; then, we tried to define whether E2 suppressed HCC cells through its upregulation of NLRP3 inflammasome. To verify this, we pretreated the HCC cells with two NLRP3 inflammasome inhibitors, Yvadcmk and Zvadcmk before treatment with E2; and further detected the cell viability, colony formation capability, and invasion capability of the HCC cells. Our data show that reconstitution of NLRP3 inflammasome reversed malignant behaviors of HCC cells in accordance with our previous observation; whereas blockage of NLRP3 inflammasome activation by its inhibitor Yvadcmk and Zvadcmk significantly abolished E2-mediated anti-tumor effect on the HCC cells (*Po0.05, **Po0.01, and ***Po0.001, Figure 6 ). These data further demonstrated that E2 inhibited HCC progression through its upregulation of NLRP3 inflammasome.
DISCUSSION
HCC is one of the most lethal malignancies with notably more prevalence in males worldwide. [18] [19] [20] The reasons for the sex disparity in HCC incidences are not fully understood. In this study, we aimed to clarify the effect of E2/ERβ/MAPK pathway-mediated NLRP3 inflammasome upregulation in HCC cells and the involvement of its deregulation in HCC progression.
Our data show that expression of estrogen receptor β (ERβ) was significantly downregulated in liver cancer cells, which correlated with advanced disease status. These data indicate an involvement of ERβ deregulation in HCC progression. On the basis of our previous data showing the same expression tendency of NLRP3 inflammasome in HCC progression, we are interested to investigate the potential link between ERβ and NLRP3 inflammasome. In this study, our data surprisingly demonstrated a significant positive correlation between the expression level of ERβ and NLRP3 inflammasome components. In vitro experiments confirmed the positive regulation of NLRP3 inflammasome by E2 through ERβ/ MAPK pathway.
Our data also show that after treatment with E2, the proliferation, migration, and colony formation capabilities of HCC cells were significantly inhibited in an ERβ/MAPK pathway-dependent manner, which is consistent with a significantly upregulated expression and activation of NLRP3 inflammasome. We further showed that treatment with inflammasome inhibitors significantly rescued the inhibitory effect of E2 on HCC cells, which verified that the effect of E2 on HCC cells was mediated, at least to a great degree by NLRP3 inflammasome activation.
Given the widespread role of E2 in human physiology, it is not surprising that estrogens are also implicated in the development and progression of many diseases including liver cancer. In contrast with early reports showing cancer promoting role of E2, recent researches showed that E2 conferred protection against cell proliferation and malignant transformation in cancer progression. This protective role of E2 in the gender disparity in hepatocarcinogenesis is recognized in recent years, and several investigations have attempted to address the importance of E2 in the pathogenesis of HCC. [3] [4] [5] 8 Naugler et al 5 showed that E2 inhibited the release of IL-6 from Kupffer's cells, which further reduced the risk of cancer in female mice in diethylnitrosamine-induced hepatic carcinogenesis. Subsequently, Yang et al 21 showed that E2 suppressed hepatic tumor growth via regulating the polarization of infiltrating macrophages. To our knowledge, this is the first study verifying the role of E2/ERβ/MAPK signaling-induced NLRP3 inflammasome activation in HCC progression. Figure 6 See for caption page on 813.
Estrogen suppression of HCC by inflammasomes Q Wei et al
